Commerce Dashboard

Biocon Ltd

Go Back

Biocon Ltd

  • Over 1,200 patent applications filed and hold around 984 patents and 448 trademark registrations globally
  • Available across 120 countries
  • Total revenue of Rs 6,529 crore (US$ 926.23 million) in FY20
  • Biocon has one of the largest global biosimilars portfolios

Biocon is Asia's premier biopharmaceutical company that is driven by the vision to make a difference to global healthcare through improved access to high quality, lifesaving biotherapeutics by making them affordable for patients across the world. Biocon is among the few companies globally to have received approvals for its biosimilars from developed countries like the U.S., EU, Australia and Japan. It’s credibility as a serious player in the biosimilars sector was first established with the Japanese approval for Insulin Glargine. The credibility was enhanced when Biocon, along with partner Mylan, became the first global company to get biosimilar Trastuzumab and Pegfilgrastim approved in the US in 2017 and 2018, respectively. It was also among the first few to receive Insulin Glargine approval in Europe and Australia for Insulin Glargine, both in partnership with Mylan. It also established its presence in key emerging markets through safe, effective and high quality biosimilars including recombinant human insulin.

Company Website:


2019 With the subsidiary of China Medical System Holdings Ltd. (CMS), Biocon has signed the license and supply agreement for three generic formulation products in Greater China.
Mylan and Biocon Launch First Trastuzumab Biosimilar, Ogivri™, in Australia
2018 Sandoz Biosimilars collaboration signed
2018 The U.S. FDA approves Fulphila™, co-developed by Biocon and Mylan and Therapeutic Goods Administration, Australia approves biosimilar Insulin Glargine, Semglee™ 100 IU/mL 3 mL prefilled pen
2014 Biocon introduced CANMAb™ - Trastuzumab for Treating Breast Cancer in India
2011 Biocon launches INSUPen®, a convenient and affordable reusable insulin delivery device
2002 Clinigene's clinical laboratory is the first in India to receive CAP accreditation
2000 Biocon commissions its first fully automated submerged fermentation plant to produce specialty pharmaceuticals and establishes Clinigene, India's first Clinical Research Organisation (CRO) to pursue clinical research and development
1997 Biocon spearheads initiatives in human healthcare through a dedicated manufacturing facility
1993 Biocon scales up its in-house research programme
1979 Biocon is the first Indian company to manufacture and export enzymes to USA and Europe
Biocon India is incorporated as a joint venture between Biocon Biochemicals Ltd. of Ireland and an Indian entrepreneur, Kiran Mazumdar-Shaw


Updated: May, 2019

Science and R&D
India ranked 52nd in the Global Innovation Index (GII), 2019 and 50th on gross expenditure in R&D.